Volume 10, Issue 2 (5-2022)
Jorjani Biomed J 2022, 10(2): 69-75 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadi M, Kohan L, Saeidi M, Saghaeian-Jazi M, Mohammadi S. Inducible Animal Models of Skin Fibrosis; Updated Review of the Literature. Jorjani Biomed J 2022; 10 (2) :69-75
URL: http://goums.ac.ir/jorjanijournal/article-1-906-en.html
URL: http://goums.ac.ir/jorjanijournal/article-1-906-en.html
1- Department of biology, Islamic Azad University, Arsanjan branch, Arsanjan, Iran.
2- Stem Cell Research center, Golestan University of Medical Sciences, Gorgan, Iran. , saeedi.m50@gmail.com
3- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
4- Stem Cell Research center, Golestan University of Medical Sciences, Gorgan, Iran.
2- Stem Cell Research center, Golestan University of Medical Sciences, Gorgan, Iran. , saeedi.m50@gmail.com
3- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
4- Stem Cell Research center, Golestan University of Medical Sciences, Gorgan, Iran.
Abstract: (2109 Views)
Fibrosis is a common and mostly progressive pathological outcome in various chronic inflammatory disorders. Dermal (skin) fibrosis, which is associated with intense skin lesions, is a result of an uncontrolled healing process in the dermis, particularly disproportionate fibroblast proliferation and extracellular matrix (ECM) production. Animal models are substantial tools in biomedical investigations and have been considerably employed to evaluate miscellaneous features of diseases that cannot be demonstrated otherwise in humans. To date, various skin fibrosis models have been generated, including the transgene and/or genetic models and chemical and drug-induced models. However, genetic models are sophisticated and need access to convoluted methods. Accordingly, the introduction of affordable and easy to generate fibrosis models in the skin is crucial. Here, we aimed to introduce the chemical/drug-induced skin fibrosis animal models to provide an updated list of available approaches.
Keywords: Fibrosis [MeSH], Models, Animal [MeSH], Skin [MeSH], Bleomycin [MeSH], Hypochlorous Acid [MeSH], Vinyl Chloride [MeSH]
Full-Text [PDF 691 kb]
(905 Downloads)
| | Full-Text (HTML) (173 Views)
To date, various skin fibrosis models have been generated, including the transgene and/or genetic models and chemical and drug-induced models.
Here, we aimed to introduce the chemical/drug-induced skin fibrosis animal models to provide an updated list of available approaches.
Type of Article: Review Article |
Subject:
Basic Medical Sciences
Received: 2022/05/30 | Accepted: 2022/05/31 | Published: 2022/06/11
Received: 2022/05/30 | Accepted: 2022/05/31 | Published: 2022/06/11
References
1. Mohammadi M, Kohan L, Saeedi M, Saghaeian Jazi M, Mohammadi S. The antifibrotic effects of naringin in a hypochlorous acid (HOCl)-induced mouse model of skin fibrosis. Immunopharmacology and Immunotoxicology. 2022:1-8. [view at publisher] [DOI] [PMID] [Google Scholar]
2. Marangoni RG, Lu TT. The roles of dermal white adipose tissue loss in scleroderma skin fibrosis. Current opinion in rheumatology. 2017;29(6):585-90. [view at publisher] [DOI] [PMID] [Google Scholar]
3. Paulin F, Doyle TJ, Fletcher EA, Ascherman DP, Rosas IO. Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis: shared mechanistic and phenotypic traits suggest overlapping disease mechanisms. Revista de investigacion clinica. 2015;67(5):280-6. [view at publisher] [Google Scholar]
4. Frangou E, Chrysanthopoulou A, Mitsios A, Kambas K, Arelaki S, Angelidou I, et al. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Annals of the Rheumatic Diseases. 2019;78(2):238-48. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
5. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature medicine. 2012;18(7):1028. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
6. Luzina IG, Atamas SP. Fibrotic skin diseases. Clinical and basic immunodermatology: Springer; 2008. p. 721-37. [DOI]
7. Smith GP, Chan ES. Molecular pathogenesis of skin fibrosis: insight from animal models. Current rheumatology reports. 2010;12(1):26-33. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
8. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nature medicine. 2010;16(11):1210-4. [view at publisher] [DOI] [PMID] [Google Scholar]
9. Masopust D, Sivula CP, Jameson SC. Of mice, dirty mice, and men: using mice to understand human immunology. The Journal of Immunology. 2017;199(2):383-8. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
10. Artlett CM. Animal models of systemic sclerosis: their utility and limitations. Open access rheumatology: research and reviews. 2014;6:65. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
11. Do N, Eming S. Skin fibrosis: Models and mechanisms. Current research in translational medicine. 2016;64(4):185-93. [view at publisher] [DOI] [PMID] [Google Scholar]
12. Starkel P, Leclercq I. Animal models for the study of hepatic fibrosis. Best practice & research Clinical gastroenterology. 2011;25(2):319-33. [view at publisher] [DOI] [PMID] [Google Scholar]
13. Avouac J. Mouse model of experimental dermal fibrosis: the bleomycin-induced dermal fibrosis. Arthritis Research: Springer; 2014. p. 91-8. [view at publisher] [DOI] [PMID] [Google Scholar]
14. Wei J, Zhu H, Komura K, Lord G, Tomcik M, Wang W, et al. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Annals of the rheumatic diseases. 2014;73(2):446-54. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
15. Watanabe M, Takabe Y, Katsumata T, Terasima T. Effects of bleomycin on progression through the cell cycle of mouse L-cells. Cancer research. 1974;34(4):878-81. [view at publisher] [Google Scholar]
16. Faroon O, Jones DG, Todd GD. Toxicological profile for vinyl chloride. 2006. [view at publisher] [Google Scholar]
17. Black C, Walker A, Catoggio L, Welsh K, Bernstein R, McGregor A, et al. Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. The Lancet. 1983;321(8314-8315):53-5. [DOI] [Google Scholar]
18. Souza CEA, Maitra D, Saed GM, Diamond MP, Moura AA, Pennathur S, et al. Hypochlorous acid-induced heme degradation from lactoperoxidase as a novel mechanism of free iron release and tissue injury in inflammatory diseases. PloS one. 2011;6(11):e27641. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
19. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chéreau C, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. The Journal of Immunology. 2009;182(9):5855-64. [view at publisher] [DOI] [PMID] [Google Scholar]
20. Bagnato G, Bitto A, Irrera N, Pizzino G, Sangari D, Cinquegrani M, et al. Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis. Arthritis research & therapy. 2013;15(5):1-12. [view at publisher] [DOI] [PMID] [PMCID] [Google Scholar]
21. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma: I. Description of model systems. Cellular immunology. 1983;77(1):1-12. [view at publisher] [DOI] [Google Scholar]
22. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. The Journal of Immunology. 1999;163(10):5693-9. [view at publisher] [Google Scholar]
23. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graft‐versus‐host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2004;50(4):1319-31. [view at publisher] [DOI] [PMID] [Google Scholar]
24. Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. Journal of investigative dermatology. 2003;121(4):713-9. [view at publisher] [DOI] [PMID] [Google Scholar]
25. Varga J, Pasche B. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nature Reviews Rheumatology. 2009;5(4):200.
https://doi.org/10.1038/nrrheum.2014.22 [view at publisher] [DOI] [Google Scholar]
26. Chujo S, Shirasaki F, Kondo‐Miyazaki M, Ikawa Y, Takehara K. Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein‐1 in skin fibrosis. Journal of cellular physiology. 2009;220(1):189-95. [view at publisher] [DOI] [PMID] [Google Scholar]
27. Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin‐6 signaling. Arthritis & Rheumatism. 2011;63(11):3575-85. [view at publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
